Provided by Tiger Trade Technology Pte. Ltd.

Jazz Pharmaceuticals PLC

225.55
-5.6400-2.44%
Volume:75.00K
Turnover:17.08M
Market Cap:14.64B
PE:15.42
High:229.16
Open:228.55
Low:225.22
Close:231.19
52wk High:266.38
52wk Low:128.80
Shares:64.91M
Float Shares:62.69M
Volume Ratio:1.90
T/O Rate:0.12%
Dividend:- -
Dividend Rate:- -
EPS(TTM):14.63
EPS(LYR):-5.8403
ROE:22.11%
ROA:6.86%
PB:3.05
PE(LYR):-38.62

Loading ...

RBC Trims Price Target on Jazz Pharmaceuticals to $296 From $299, Keeps Outperform Rating

MT Newswires Live
·
2 hours ago

Jazz Pharmaceuticals Plc : RBC Cuts Target Price to $296 from $299

THOMSON REUTERS
·
3 hours ago

Jazz Pharma President and CEO Renee D. Gala Sells 2,000 Ordinary Shares for $472,800

Reuters
·
16 hours ago

Jazz Pharmaceuticals is Maintained at Buy by Truist Securities

Dow Jones
·
20 hours ago

Jazz Pharmaceuticals price target raised to $286 from $281 at Truist

TIPRANKS
·
Yesterday

Jazz Pharma Director Bruce C. Cozadd Disposes of 6,000 Shares Worth $1,381,980

Reuters
·
Oct 06

ADPT, MRNA, CRWV, NBIS, JAZZ trending with analysts

TIPRANKS
·
Oct 03

Jazz Pharmaceuticals Initiated at Buy by Citigroup

Dow Jones
·
Sep 30

Jazz Pharmaceuticals Plc : Citigroup Initiates Coverage with Buy Rating; Target Price $325

THOMSON REUTERS
·
Sep 30

Citigroup Initiates Jazz Pharmaceuticals at Buy With $325 Price Target

MT Newswires Live
·
Sep 30

US Research Roundup-Alnylam Pharmaceuticals, Carvana, MongoDB

Reuters
·
Sep 30

Bernstein Reaffirms Their Hold Rating on Jazz Pharmaceuticals (JAZZ)

TIPRANKS
·
Sep 26

Goldman Sachs Resumes Coverage with a Buy Rating on Jazz Pharmaceuticals (JAZZ)

TIPRANKS
·
Sep 24

Jazz Reprices USD 1.9 Billion Term Loan, Extends Maturity to 2033

Reuters
·
Sep 24

Jazz Pharmaceuticals - Unit Enters Amendment No. 4 to Credit Agreement on Sept 23, 2026 - SEC Filing

THOMSON REUTERS
·
Sep 24

Jazz Pharmaceuticals - Unit Borrows $273.31 Mln in Additional Tranche B-3 Dollar Term Loans - SEC Filing

THOMSON REUTERS
·
Sep 24

Nvidia, QIA-Backed Iambic Therapeutics Files for US IPO as Biotech Boom Rolls On

Reuters
·
Sep 22

Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences

THOMSON REUTERS
·
Sep 15

Jazz Pharmaceuticals Sees Meaningful Long-Term Value From Ziihera's Pursuits Beyond GEA, UBS Says

MT Newswires Live
·
Sep 12

Jazz Pharmaceuticals Price Target Raised to $337.00/Share from $315.00 by UBS

Dow Jones
·
Sep 11